Marc Damelin

Marc Damelin

Company: Mersana Therapeutics Inc.

Job title: Executive Director and Head of Biology


Marc Damelin is Executive Director and Head of Biology at Mersana Therapeutics, where he is focused on antibody-drug conjugate (ADC) discovery and development for cancer. Prior, he spent 10 years at Pfizer, where he led ADC project teams, oversaw the ADC discovery portfolio and mentored two postdoctoral fellows. He is the Editor of the book “Innovations for Next-Generation Antibody-Drug Conjugates” published by Springer in 2018. Marc received his Ph.D. in Biophysics from Harvard University and was a Postdoctoral Fellow of the Damon Runyon Cancer Research Foundation at Columbia University. 


Live Q&A 3:10 pm

Read more

day: Online Conference

Tumor Targeting of a STING Agonist by Means of an Antibody-Drug Conjugate Induces Potent Anti-Tumor Immune Responses 2:10 pm

• Mersana has developed the Immunosynthen platform to enable tumor-targeted delivery of a STING agonist by means of antibody-drug conjugates (ADC) • Targeted STING-agonist ADCs induce potent anti-tumor immune responses and outperform systemically administered STING agonist. • Targeted STING-agonist ADCs induce significantly lower levels of systemic cytokines than free STING agonistRead more

day: Online Conference

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.